Melinta Therapeutics Lands $67,000,000 New Financing

  • Feed Type
  • Date
    6/10/2015
  • Company Name
    Melinta Therapeutics
  • Mailing Address
    300 George Street New Haven, CT 06511 USA
  • Company Description
    Melinta Therapeutics’ mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.
  • Website
    http://www.melinta.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $67,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds from the financing will be used to complete the final Phase 3 study of delafloxacin, an investigational fluoroquinolone, currently undergoing a confirmatory Phase 3 study for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Funds will also support the potential submission of a New Drug Application (NDA) for delafloxacin for the lead indication, pursuing new indications for delafloxacin including hospital-treated community-acquired bacterial pneumonia (hCABP), and advancing a lead candidate for the company’s ESKAPE pathogen program.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy